1.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33(4):451–458.
2.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. ANN INTERN MED 1985, 103(4):620–625.
3.Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS: Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group. HAEMATOLOGICA 2012, 97(11):1770–1773.
4.Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo NL, Menna G, Micalizzi C et al: Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. BLOOD 2013, 122(2):170–178.
5.Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991, 78(3):325–329.
6.Stam RW, Hubeek I, den Boer ML, Buijs-Gladdines JG, Creutzig U, Kaspers GJ, Pieters R: MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. LEUKEMIA 2006, 20(1):179–182.
7.Cheng Z, Hu K, Tian L, Dai Y, Pang Y, Cui W, Zhao H, Qin T, Han Y, Hu N et al: Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5. CANCER GENE THER 2018, 25(3–4):77–83.
8.Manola KN, Panitsas F, Polychronopoulou S, Daraki A, Karakosta M, Stavropoulou C, Avgerinou G, Hatzipantelis E, Pantelias G, Sambani C et al: Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet 2013, 206(3):63–72.
9.Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE et al: Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J CLIN ONCOL 2015, 33(27):2949–2962.
10.von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA et al: Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J CLIN ONCOL 2010, 28(16):2682–2689.
11.Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA et al: Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma 2014, 55(7):1523–1532.
12.Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnukainen K, Jonsson OG, Zeller B et al: Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. BLOOD 2011, 118(22):5905–5913.
13.Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN et al: Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. BLOOD 2009, 114(12):2489–2496.
14.Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A et al: Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. BLOOD 2012, 120(16):3187–3205.
15.Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ et al: Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biol Blood Marrow Transplant 2016, 22(12):2235–2242.
16.Zhao XS, Qin YZ, Liu YR, Chang YJ, Xu LP, Zhang XH, Huang XJ: The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leuk Lymphoma 2017, 58(5):1135–1143.
17.de Lima MC, Da SD, Freund AP, Dacoregio JS, Costa TJ, Costa I, Faraco D, Silva ML: Acute Myeloid Leukemia: analysis of epidemiological profile and survival rate. J Pediatr (Rio J) 2016, 92(3):283–289.
18.Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, Kobayashi R, Tawa A, Kosaka Y, Kato K et al: Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol 2012, 159(2):204–210.
19.Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C et al: Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. BLOOD 2013, 122(1):37–43.
20.Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R et al: Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J CLIN ONCOL 2009, 27(24):4007–4013.
21.Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ et al: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. CANCER-AM CANCER SOC 2012, 118(3):761–769.
22.Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, Kaspers GJ, de Graaf SS, Harbott J, Creutzig U et al: Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. LEUKEMIA 2009, 23(2):262–270.
23.Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B et al: Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. BLOOD 2009, 113(26):6558–6566.
24.Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H et al: Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. BLOOD CANCER J 2014, 4:e226.
25.Klein K, de Haas V, Bank I, Beverloo HB, Zwaan CM, Kaspers GL: Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). PEDIATR BLOOD CANCER 2017, 64(10).
26.Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ et al: Clinical implications of FLT3 mutations in pediatric AML. BLOOD 2006, 108(12):3654–3661.
27.Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG: Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children’s Oncology Group. J CLIN ONCOL 2008, 26(35):5797–5801.
28.Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR: Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2013, 19(7):1021–1025.
29.Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M, Yabe H, Nakazawa Y, Koh K, Goto H et al: Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML–05 clinical trial. PEDIATR BLOOD CANCER 2019, 66(10):e27875.
30.Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L et al: Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J CLIN ONCOL 2014, 32(27):3021–3032.